F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography in Intrahepatic Cholangiocarcinoma: Could It Be a New Paradigm?

Overview

Journal Hepatobiliary Surg Nutr

Publisher AME Publishing Company

Date 2024 Apr 15

PMID 38617483

Authors

Masakatsu Tsurusaki

Ryohei Kozuki

Atsushi Urase

Affiliations

Soon will be listed here.

Citing Articles

Application value of F-FDG PET/CT in soft tissue metastasis of intrahepatic cholangiocarcinoma: a case report and literature review.

Liu S, Sun X, Liu Y, Shi N, Zhang X, Yu Y Front Oncol. 2025; 14:1474105.

PMID: 39886669 PMC: 11779615. DOI: 10.3389/fonc.2024.1474105.

References

Zhang H, Yang T, Wu M, Shen F . Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management. Cancer Lett. 2015; 379(2):198-205. DOI: 10.1016/j.canlet.2015.09.008. View

Banales J, Marin J, Lamarca A, Rodrigues P, Khan S, Roberts L . Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020; 17(9):557-588. PMC: 7447603. DOI: 10.1038/s41575-020-0310-z. View

Moris D, Palta M, Kim C, Allen P, Morse M, Lidsky M . Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2022; 73(2):198-222. DOI: 10.3322/caac.21759. View

Nishioka E, Tsurusaki M, Kozuki R, Im S, Kono A, Kitajima K . Comparison of Conventional Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Diagnostic Accuracy of Staging in Patients with Intrahepatic Cholangiocarcinoma. Diagnostics (Basel). 2022; 12(11). PMC: 9689116. DOI: 10.3390/diagnostics12112889. View

Vithayathil M, Khan S . Current epidemiology of cholangiocarcinoma in Western countries. J Hepatol. 2022; 77(6):1690-1698. DOI: 10.1016/j.jhep.2022.07.022. View

Mavros M, Economopoulos K, Alexiou V, Pawlik T . Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. JAMA Surg. 2014; 149(6):565-74. DOI: 10.1001/jamasurg.2013.5137. View

Tsurusaki M, Okada M, Kuroda H, Matsuki M, Ishii K, Murakami T . Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor. J Gastroenterol. 2013; 49(1):46-56. PMC: 3895191. DOI: 10.1007/s00535-013-0790-5. View

Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81. DOI: 10.1056/NEJMoa0908721. View

Bowlus C, Arrive L, Bergquist A, Deneau M, Forman L, Ilyas S . AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2022; 77(2):659-702. DOI: 10.1002/hep.32771. View

10.

. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023; 79(1):181-208. DOI: 10.1016/j.jhep.2023.03.010. View

11.

Pichlmayr R, Weimann A, Klempnauer J, Oldhafer K, Maschek H, Tusch G . Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg. 1996; 224(5):628-38. PMC: 1235440. DOI: 10.1097/00000658-199611000-00007. View

12.

Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A . Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010; 103(4):469-74. PMC: 2939781. DOI: 10.1038/sj.bjc.6605779. View

13.

Jadvar H, Henderson R, Conti P . [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. J Comput Assist Tomogr. 2007; 31(2):223-8. DOI: 10.1097/01.rct.0000237811.88251.d7. View

14.

Lin Y, Chong H, Song G, Zhang C, Dong L, Aye L . The influence of F-fluorodeoxyglucose positron emission tomography/computed tomography on the N- and M-staging and subsequent clinical management of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2022; 11(5):684-695. PMC: 9577996. DOI: 10.21037/hbsn-21-25. View